...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>PACE: Pacing and clinical electrophysiology >Prophylactic high-dose oral-N-acetylcysteine does not prevent atrial fibrillation after heart surgery: A prospective double blind placebo-controlled randomized clinical trial
【24h】

Prophylactic high-dose oral-N-acetylcysteine does not prevent atrial fibrillation after heart surgery: A prospective double blind placebo-controlled randomized clinical trial

机译：预防性大剂量口服N-乙酰半胱氨酸不能预防心脏手术后的房颤：前瞻性双盲安慰剂对照的随机临床试验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aims Postoperative atrial fibrillation (POAF) following cardiac surgery is a frequent complication with multifactorial etiologies. Recently inflammation due to enhanced oxidative stress has been implicated in its pathogenesis. N-acetylcysteine (NAC) is a promising and novel antioxidant agent. The purpose of this study was to evaluate the efficacy of high-dose oral-NAC for prevention of POAF. Methods Two hundred and forty patients were randomized in this prospective, double blind placebo-controlled trial to either 1,200-mg oral-NAC two times a day (n = 120) or placebo (n = 120) starting 48 hours before and up to 72 hours after open heart surgery. Results The mean age was about 60 years, and 75% were male. Patients in the NAC group were older, with higher percentage of acute coronary syndrome, hypercholesterolemia, and left internal mammary artery use. Coronary involvement and hypertension were more prevalent in the placebo group. All other baseline patient characteristics were similar between groups. Overall POAF developed in 13.8% of the patients. There was no difference in the incidence of POAF between the NAC vs placebo groups (11.7% vs 15.8%, respectively; P = 0.34). Postoperative hospital stay, morbidity, and mortality were similar in both groups. Conclusions Prophylactic high-dose oral-NAC begun 2 days before open heart surgery and continued for 5 days, and had no significant effect on the incidence of POAF, in-hospital stay, and postoperative morbidity or mortality.
机译：目的心脏手术后的术后房颤（POAF）是多因素病因的常见并发症。最近，由于氧化应激增强而引起的炎症涉及其发病机理。 N-乙酰半胱氨酸（NAC）是一种有前途的新型抗氧化剂。这项研究的目的是评估大剂量口服NAC预防POAF的功效。方法在这项前瞻性，双盲安慰剂对照试验中，将240例患者随机分为两组，每天两次（n = 120）口服安慰剂（n = 120）或安慰剂（n = 120），开始于48小时前至72天。心脏直视手术后数小时。结果平均年龄约60岁，男性占75％。 NAC组的患者年龄较大，急性冠状动脉综合征，高胆固醇血症和使用左乳内动脉的百分比更高。在安慰剂组中，冠脉受累和高血压更为普遍。两组之间所有其他基线患者特征相似。总体POAF发生在13.8％的患者中。 NAC组和安慰剂组之间POAF的发生率没有差异（分别为11.7％和15.8％; P = 0.34）。两组的术后住院时间，发病率和死亡率相似。结论预防性大剂量口服NAC在心脏直视手术前2天开始，持续5天，对POAF的发生率，住院时间和术后发病率或死亡率均无明显影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号